Equillium (EQ) Financials

Equillium logo
$1.06 -0.06 (-5.36%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.05 -0.01 (-1.32%)
As of 11/20/2026 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Equillium

Annual Income Statements for Equillium

This table shows Equillium's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-13 -26 -30 -39 -62 -13 -8.07 -22
Consolidated Net Income / (Loss)
-13 -26 -30 -39 -62 -13 -8.07 -22
Net Income / (Loss) Continuing Operations
-13 -26 -30 -39 -62 -13 -8.07 -22
Total Pre-Tax Income
-13 -26 -30 -39 -62 -13 -7.71 -22
Total Operating Income
-8.62 -27 -30 -38 -62 -15 -8.27 -24
Total Gross Profit
0.00 0.00 0.00 0.00 16 36 41 0.00
Total Revenue
0.00 0.00 0.00 0.00 16 36 41 0.00
Operating Revenue
- - - 0.00 16 36 41 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
8.62 27 30 38 78 51 49 24
Selling, General & Admin Expense
3.67 9.09 10 11 17 14 12 11
Research & Development Expense
4.94 18 19 26 61 37 37 13
Total Other Income / (Expense), net
-4.64 1.13 -0.27 -1.02 -0.35 1.77 0.56 1.24
Interest & Investment Income
0.34 1.39 0.48 0.06 0.42 2.33 1.38 0.83
Other Income / (Expense), net
-2.42 0.02 0.36 - 0.28 -0.08 -0.82 0.40
Income Tax Expense
- - - - 0.00 0.58 0.36 0.00
Basic Earnings per Share
($1.09) ($1.47) ($1.46) ($1.36) ($1.85) ($0.38) ($0.23) ($0.39)
Weighted Average Basic Shares Outstanding
12.19M 17.38M 20.36M 28.81M 33.73M 34.73M 35.36M 57.30M
Diluted Earnings per Share
($1.09) ($1.47) ($1.46) ($1.36) ($1.85) ($0.38) ($0.23) ($0.39)
Weighted Average Diluted Shares Outstanding
12.19M 17.38M 20.36M 28.81M 33.73M 34.73M 35.36M 57.30M
Weighted Average Basic & Diluted Shares Outstanding
12.19M 17.38M 20.36M 28.81M 34.41M 35.25M 35.61M 63.23M

Quarterly Income Statements for Equillium

This table shows Equillium's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-2.73 0.47 -0.01 -5.79 -8.65 -5.74 -4.23 -3.78 -5.31 -4.69 -4.58
Consolidated Net Income / (Loss)
-2.73 0.47 -0.01 -5.79 -8.65 -5.74 -4.23 -3.78 -5.31 -4.69 -4.58
Net Income / (Loss) Continuing Operations
-2.73 0.47 -0.01 -5.79 -8.65 -5.74 -4.23 -3.78 -5.31 -4.69 -4.58
Total Pre-Tax Income
-2.73 0.47 -0.01 -5.43 -8.65 -5.74 -4.23 -3.78 -5.31 -4.69 -4.58
Total Operating Income
-2.79 -0.10 -0.68 -4.70 -8.87 -6.23 -4.58 -3.96 -5.61 -5.16 -5.05
Total Gross Profit
11 14 12 4.39 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue
11 14 12 4.39 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Revenue
11 14 12 4.39 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
13 14 13 9.09 8.87 6.23 4.58 3.96 5.61 5.16 5.05
Selling, General & Admin Expense
3.74 3.15 3.28 1.78 2.95 2.15 3.27 2.43 2.62 2.41 2.56
Research & Development Expense
9.74 11 9.56 7.32 5.92 4.08 1.30 1.54 2.99 2.75 2.49
Total Other Income / (Expense), net
0.06 0.57 0.67 -0.73 0.22 0.49 0.35 0.19 0.30 0.46 0.47
Interest & Investment Income
0.44 0.37 0.33 0.24 0.17 0.12 0.24 0.30 0.31 0.51 0.49
Other Income / (Expense), net
-0.38 0.20 0.34 -0.97 0.04 0.37 0.11 -0.12 -0.01 -0.05 -0.03
Basic Earnings per Share
($0.08) $0.01 $0.00 ($0.16) ($0.24) ($0.16) ($0.06) $0.07 ($0.06) ($0.04) ($0.04)
Weighted Average Basic Shares Outstanding
35.25M 35.29M 35.42M 35.36M 35.59M 35.72M 65.32M 57.30M 96.28M 111.81M 111.92M
Diluted Earnings per Share
($0.08) $0.01 $0.00 ($0.16) ($0.24) ($0.16) ($0.06) $0.07 ($0.06) ($0.04) ($0.04)
Weighted Average Diluted Shares Outstanding
35.25M 36.59M 35.42M 35.36M 35.59M 35.72M 65.32M 57.30M 96.28M 111.81M 111.92M
Weighted Average Basic & Diluted Shares Outstanding
35.25M 35.42M 35.43M 35.61M 35.72M 59.50M 60.89M 63.23M 63.23M 63.41M 82.32M

Annual Cash Flow Statements for Equillium

This table details how cash moves in and out of Equillium's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
21 -15 11 26 8.74 -36 -5.13 12
Net Cash From Operating Activities
-7.53 -23 -25 -32 -8.73 -22 -19 -23
Net Cash From Continuing Operating Activities
-7.53 -23 -25 -32 -8.81 -22 -19 -23
Net Income / (Loss) Continuing Operations
-13 -26 -30 -39 -62 -13 -8.07 -22
Consolidated Net Income / (Loss)
-13 -26 -30 -39 -62 -13 -8.07 -22
Depreciation Expense
0.01 0.02 0.05 0.07 0.12 0.13 0.14 0.12
Amortization Expense
- -0.32 0.36 0.55 0.33 -0.73 -0.75 -0.01
Non-Cash Adjustments To Reconcile Net Income
5.42 2.23 3.53 4.65 28 4.06 4.54 1.87
Changes in Operating Assets and Liabilities, net
0.30 0.71 1.26 1.74 25 -12 -15 -2.36
Net Cash From Investing Activities
-37 -2.17 -19 27 19 -4.76 14 4.46
Net Cash From Continuing Investing Activities
-37 -2.17 -19 27 19 -4.76 14 4.46
Purchase of Property, Plant & Equipment
-0.04 -0.07 -0.20 -0.06 -0.28 -0.05 -0.09 -0.05
Purchase of Investments
-37 -55 -56 -33 -15 -55 -18 0.00
Sale of Property, Plant & Equipment
- - - - - - 0.00 0.01
Sale and/or Maturity of Investments
- 53 37 60 33 50 32 4.50
Net Cash From Financing Activities
66 9.84 54 31 -1.22 -9.23 0.16 30
Net Cash From Continuing Financing Activities
66 9.84 54 31 -1.22 -9.23 0.16 30
Issuance of Common Equity
64 0.04 54 30 0.21 0.17 0.16 29
Other Financing Activities, net
0.29 0.07 0.01 0.89 - 0.00 0.00 1.84
Effect of Exchange Rate Changes
- -0.01 0.03 -0.00 0.01 - -0.08 0.05
Cash Income Taxes Paid
- - - - 0.00 0.58 0.00 0.35

Quarterly Cash Flow Statements for Equillium

This table details how cash moves in and out of Equillium's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-12 -0.51 4.39 2.64 -3.58 -3.01 22 -2.84 31 -4.16 -3.84
Net Cash From Operating Activities
-8.80 0.73 -7.66 -3.30 -8.17 -3.01 -8.43 -3.13 -4.30 -4.11 -3.83
Net Cash From Continuing Operating Activities
-8.80 0.74 -7.66 -3.29 -8.17 -3.01 -8.41 -3.20 -4.30 -4.15 -3.81
Net Income / (Loss) Continuing Operations
-2.73 0.47 -0.01 -5.79 -8.65 -5.74 -4.23 -3.78 -5.31 -4.69 -4.58
Consolidated Net Income / (Loss)
-2.73 0.47 -0.01 -5.79 -8.65 -5.74 -4.23 -3.78 -5.31 -4.69 -4.58
Depreciation Expense
0.03 0.04 0.04 0.04 0.03 0.03 0.03 0.02 0.02 0.03 0.02
Non-Cash Adjustments To Reconcile Net Income
1.36 0.73 0.66 1.80 0.57 0.19 0.29 0.81 0.94 1.13 1.27
Changes in Operating Assets and Liabilities, net
-7.17 -0.25 -8.19 0.74 -0.10 2.50 -4.50 -0.26 0.05 -0.62 -0.52
Net Cash From Financing Activities
0.00 0.09 - 0.07 0.09 -0.02 30 0.28 35 0.04 -0.00
Net Cash From Continuing Financing Activities
0.00 0.09 - 0.07 0.09 -0.02 30 0.28 35 0.04 -0.00
Other Financing Activities, net
0.00 - - 0.00 0.04 - 1.19 0.60 0.45 0.14 -0.00
Effect of Exchange Rate Changes
-0.02 0.02 0.05 -0.13 -0.00 0.02 -0.01 0.04 - - -0.02

Annual Balance Sheets for Equillium

This table presents Equillium's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
7.15 67 56 85 85 78 51 26 32
Total Current Assets
7.15 67 55 85 83 77 49 25 31
Cash & Equivalents
7.10 29 13 24 50 59 23 18 30
Short-Term Investments
0.00 37 40 58 30 12 18 4.49 0.00
Prepaid Expenses
0.05 1.19 2.29 3.01 2.66 2.87 4.75 2.40 0.76
Plant, Property, & Equipment, net
0.00 0.06 0.09 0.24 0.24 0.39 0.32 0.26 0.16
Total Noncurrent Assets
0.00 0.00 0.02 0.02 1.80 1.30 0.87 0.36 0.69
Other Noncurrent Operating Assets
- - 0.02 0.02 1.80 1.30 0.87 0.36 0.69
Total Liabilities & Shareholders' Equity
7.15 67 56 85 85 78 51 26 32
Total Liabilities
9.40 2.23 14 16 19 46 28 6.54 3.29
Total Current Liabilities
0.57 2.03 3.88 7.25 8.92 32 28 6.36 2.93
Accounts Payable
0.24 1.12 1.87 2.77 1.23 3.98 4.71 2.68 0.76
Accrued Expenses
0.33 0.91 2.01 2.81 5.89 7.24 6.70 3.48 1.82
Other Current Liabilities
- - - - 0.38 0.41 0.44 0.20 0.36
Total Noncurrent Liabilities
8.83 0.20 9.81 8.33 9.99 14 0.38 0.19 0.36
Other Noncurrent Operating Liabilities
0.78 0.20 0.13 0.05 1.24 0.82 0.38 0.19 0.36
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-2.25 65 42 70 67 32 23 19 29
Total Preferred & Common Equity
-2.25 65 42 70 67 32 23 19 29
Total Common Equity
-2.25 65 42 70 67 32 23 19 29
Common Stock
0.01 80 83 141 177 204 208 212 244
Retained Earnings
-2.26 -16 -41 -71 -110 -172 -186 -194 -216
Accumulated Other Comprehensive Income / (Loss)
0.00 0.01 0.02 -0.30 -0.14 0.08 0.14 0.78 0.36

Quarterly Balance Sheets for Equillium

This table presents Equillium's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
55 44 43 34 17 12 35 63 59 56
Total Current Assets
54 42 42 34 16 12 34 62 58 55
Cash & Equivalents
34 12 11 15 15 11 33 61 57 53
Short-Term Investments
12 21 22 10 0.00 0.00 0.00 0.00 0.00 0.00
Prepaid Expenses
3.84 5.15 2.70 2.76 1.71 0.46 0.46 0.95 0.81 1.63
Plant, Property, & Equipment, net
0.31 0.36 0.33 0.29 0.23 0.20 0.17 0.21 0.19 0.16
Total Noncurrent Assets
1.00 0.76 0.65 0.52 0.28 0.25 0.75 0.59 0.50 0.70
Other Noncurrent Operating Assets
1.00 0.76 0.65 0.52 0.28 0.25 0.75 0.59 0.50 0.70
Total Liabilities & Shareholders' Equity
55 44 43 34 17 12 35 63 59 56
Total Liabilities
31 23 20 11 6.15 7.34 3.57 3.60 2.65 3.13
Total Current Liabilities
28 22 20 11 6.00 7.23 3.09 3.35 2.48 2.82
Accounts Payable
3.64 2.78 4.49 3.67 3.06 4.81 1.08 1.30 0.85 0.68
Accrued Expenses
8.30 5.65 6.90 5.05 2.80 2.27 1.74 1.61 1.22 1.69
Other Current Liabilities
0.43 0.42 0.35 0.27 0.15 0.15 0.27 0.44 0.41 0.45
Total Noncurrent Liabilities
2.92 0.30 0.26 0.22 0.15 0.11 0.47 0.25 0.17 0.31
Other Noncurrent Operating Liabilities
0.50 0.30 0.26 0.22 0.15 0.11 0.47 0.25 0.17 0.31
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
24 21 22 23 11 5.06 31 59 56 53
Total Preferred & Common Equity
24 21 22 23 11 5.06 31 59 56 53
Total Common Equity
24 21 22 23 11 5.06 31 59 56 53
Common Stock
207 209 210 211 212 213 243 281 282 283
Retained Earnings
-183 -188 -188 -188 -202 -208 -212 -222 -226 -231
Accumulated Other Comprehensive Income / (Loss)
0.46 0.42 0.25 -0.00 0.73 0.39 0.27 0.37 0.38 0.37

Annual Metrics And Ratios for Equillium

This table displays calculated financial ratios and metrics derived from Equillium's official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
17,376,236.00 17,376,236.00 24,727,544.00 29,390,898.00 34,352,084.00 35,119,248.00 35,430,763.00 60,893,283.00
DEI Adjusted Shares Outstanding
17,376,236.00 17,376,236.00 24,727,544.00 29,390,898.00 34,352,084.00 35,119,248.00 35,430,763.00 60,893,283.00
DEI Earnings Per Adjusted Shares Outstanding
-0.76 -1.47 -1.21 -1.32 -1.82 -0.38 -0.23 -0.37
Growth Metrics
- - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 128.97% 13.89% -100.00%
EBITDA Growth
0.00% -144.93% -6.57% -29.12% -65.08% 75.21% 36.18% -138.35%
EBIT Growth
0.00% -142.13% -9.28% -29.45% -63.54% 76.38% 37.75% -155.65%
NOPAT Growth
0.00% -210.24% -10.55% -27.88% -64.28% 76.61% 43.06% -185.81%
Net Income Growth
0.00% -93.21% -16.46% -30.99% -59.86% 78.64% 39.51% -177.65%
EPS Growth
0.00% -34.86% 0.68% 6.85% -36.03% 79.46% 39.47% -69.57%
Operating Cash Flow Growth
0.00% -204.93% -7.30% -30.28% 72.78% -149.43% 12.66% -19.55%
Free Cash Flow Firm Growth
0.00% 0.00% -10.27% -24.39% 30.00% -26.78% 6.51% 10.65%
Invested Capital Growth
0.00% -65.03% -46.72% -70.10% -647.96% 39.28% 80.79% 52.19%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% -15.36% -10.50% -100.00%
EBITDA Q/Q Growth
0.00% -15.81% -3.07% -4.11% 17.16% -63.86% -39.19% 6.67%
EBIT Q/Q Growth
0.00% -14.46% -3.53% -3.90% 17.06% -63.82% -45.23% 6.42%
NOPAT Q/Q Growth
0.00% -14.52% -4.80% -3.90% 16.68% -56.49% -22.14% 3.03%
Net Income Q/Q Growth
0.00% -11.19% -4.75% -4.56% 17.67% -62.23% -74.80% 8.27%
EPS Q/Q Growth
0.00% -6.52% 6.41% -3.03% 21.28% -100.00% -76.92% 37.10%
Operating Cash Flow Q/Q Growth
0.00% -29.35% 3.07% -6.23% 81.26% -287.69% 11.06% 0.72%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 4.48% -6.74% 65.90% -327.51% 15.14% -4.54%
Invested Capital Q/Q Growth
0.00% 55.94% 6.59% 15.54% -399.47% 17.59% -30.15% 22.97%
Profitability Metrics
- - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% -389.28% -42.14% -23.61% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% -393.91% -40.25% -20.12% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% -392.13% -40.46% -22.11% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% -396.14% -36.96% -19.63% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 100.64% 100.00% 104.55% 104.68% 100.00%
Interest Burden Percent
120.11% 95.84% 102.13% 102.69% 101.02% 87.38% 84.80% 96.41%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-42.28% -47.95% -53.38% -57.28% -126.83% -48.92% -38.75% -93.99%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% -75.44% -22.64% -23.87% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% -76.21% -20.68% -21.19% 0.00%
Return on Common Equity (ROCE)
-42.28% -47.95% -53.38% -57.28% -126.83% -48.92% -38.75% -93.99%
Return on Equity Simple (ROE_SIMPLE)
-20.41% -61.17% -42.68% -58.72% -195.44% -59.08% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-6.03 -19 -21 -26 -43 -10 -5.79 -17
NOPAT Margin
0.00% 0.00% 0.00% 0.00% -275.74% -28.17% -14.09% 0.00%
Net Nonoperating Expense Percent (NNEP)
-10.95% -12.60% -15.78% -17.66% -28.62% -6.16% -7.18% -22.15%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - -45.03% -30.37% -57.85%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 109.39% 37.60% 29.04% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 384.52% 102.65% 91.08% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 493.91% 140.25% 120.12% 0.00%
Earnings before Interest and Taxes (EBIT)
-11 -27 -29 -38 -62 -15 -9.09 -23
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-11 -27 -29 -37 -61 -15 -9.70 -23
Valuation Ratios
- - - - - - - -
Price to Book Value (P/BV)
2.18 1.40 1.89 1.67 1.14 1.12 1.39 3.30
Price to Tangible Book Value (P/TBV)
2.18 1.40 1.89 1.67 1.14 1.12 1.39 3.30
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 2.31 0.70 0.65 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.10 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - -
Debt to Equity
0.00 0.23 0.14 0.15 0.28 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.23 0.12 0.13 0.10 0.00 0.00 0.00
Financial Leverage
-1.02 -1.02 -1.04 -1.05 -1.35 -1.89 -1.52 -1.11
Leverage Ratio
1.19 1.15 1.26 1.25 1.66 2.37 1.83 1.21
Compound Leverage Factor
1.42 1.10 1.29 1.29 1.68 2.07 1.55 1.16
Debt to Total Capital
0.00% 18.79% 12.46% 13.27% 21.89% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 2.09% 1.86% 13.97% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 18.79% 10.37% 11.41% 7.92% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 81.21% 87.54% 86.73% 78.11% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 -0.36 -0.35 -0.27 -0.15 0.00 0.00 0.00
Net Debt to EBITDA
0.00 1.61 2.51 1.90 1.01 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 -0.36 -0.29 -0.24 -0.05 0.00 0.00 0.00
Debt to NOPAT
0.00 -0.52 -0.48 -0.38 -0.21 0.00 0.00 0.00
Net Debt to NOPAT
0.00 2.32 3.49 2.67 1.43 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 -0.52 -0.40 -0.33 -0.07 0.00 0.00 0.00
Altman Z-Score
38.48 1.06 3.90 1.30 -4.32 -4.32 -6.86 6.37
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - -
Current Ratio
33.09 14.28 11.76 9.35 2.40 1.79 3.93 10.58
Quick Ratio
32.50 13.69 11.34 9.05 2.31 1.62 3.55 10.32
Cash Flow Metrics
- - - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -18 -20 -25 -17 -22 -21 -18
Operating Cash Flow to CapEx
-21,502.86% -31,012.16% -12,190.10% -56,282.46% -3,130.11% -43,566.00% -22,383.53% -63,183.33%
Free Cash Flow to Firm to Interest Expense
0.00 -64.78 -18.13 -23.10 -16.48 -44.81 0.00 0.00
Operating Cash Flow to Interest Expense
-2.94 -82.25 -22.41 -29.90 -8.29 -44.36 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
-2.96 -82.52 -22.59 -29.95 -8.56 -44.47 0.00 0.00
Efficiency Ratios
- - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.19 0.56 1.08 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 10.98 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 50.19 102.22 142.44 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 33.24 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 33.24 0.00 0.00
Capital & Investment Metrics
- - - - - - - -
Invested Capital
-0.98 -1.61 -2.37 -4.03 -30 -18 -3.51 -1.68
Invested Capital Turnover
0.00 0.00 0.00 0.00 -0.92 -1.49 -3.77 0.00
Increase / (Decrease) in Invested Capital
0.00 -0.64 -0.75 -1.66 -26 12 15 1.83
Enterprise Value (EV)
76 15 60 40 -26 -15 3.93 64
Market Capitalization
142 59 132 111 36 25 27 94
Book Value per Share
$3.74 $2.41 $2.82 $2.26 $0.93 $0.64 $0.54 $0.47
Tangible Book Value per Share
$3.74 $2.41 $2.82 $2.26 $0.93 $0.64 $0.54 $0.47
Total Capital
65 52 80 77 41 23 19 29
Total Debt
0.00 9.68 9.94 10 8.95 0.00 0.00 0.00
Total Long-Term Debt
0.00 9.68 8.28 8.75 3.24 0.00 0.00 0.00
Net Debt
-66 -43 -72 -71 -62 -41 -23 -30
Capital Expenditures (CapEx)
0.04 0.07 0.20 0.06 0.28 0.05 0.09 0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-0.84 -1.60 -2.57 -4.83 -21 -19 -3.95 -2.17
Debt-free Net Working Capital (DFNWC)
65 52 80 76 50 22 19 28
Net Working Capital (NWC)
65 52 78 74 45 22 19 28
Net Nonoperating Expense (NNE)
7.22 6.89 9.13 13 19 3.17 2.28 5.85
Net Nonoperating Obligations (NNO)
-66 -43 -72 -71 -62 -41 -23 -30
Total Depreciation and Amortization (D&A)
0.01 -0.29 0.41 0.62 0.45 -0.61 -0.62 0.10
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% -130.80% -52.90% -9.62% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 319.89% 60.35% 45.31% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 283.63% 60.35% 45.31% 0.00%
Earnings Adjustments
- - - - - - - -
Adjusted Basic Earnings per Share
($1.09) ($1.47) ($1.46) ($1.36) ($1.85) ($0.38) ($0.23) ($0.39)
Adjusted Weighted Average Basic Shares Outstanding
17.38M 17.62M 29.04M 34.28M 33.73M 34.73M 35.36M 57.30M
Adjusted Diluted Earnings per Share
($1.09) ($1.47) ($1.46) ($1.36) ($1.85) ($0.38) ($0.23) ($0.39)
Adjusted Weighted Average Diluted Shares Outstanding
17.38M 17.62M 29.04M 34.28M 33.73M 34.73M 35.36M 57.30M
Adjusted Basic & Diluted Earnings per Share
($1.09) ($1.47) ($1.46) ($1.36) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
12.19M 17.38M 20.36M 28.81M 34.41M 35.25M 35.61M 63.23M
Normalized Net Operating Profit after Tax (NOPAT)
-6.03 -19 -21 -26 -43 -10 -5.79 -17
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% -275.74% -28.17% -14.09% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% -396.14% -35.35% -18.75% 0.00%
Debt Service Ratios
- - - - - - - -
EBIT to Interest Expense
-4.31 -95.74 -26.56 -35.22 -58.68 -29.73 0.00 0.00
NOPAT to Interest Expense
-2.36 -67.06 -18.82 -24.65 -41.27 -20.70 0.00 0.00
EBIT Less CapEx to Interest Expense
-4.33 -96.01 -26.74 -35.27 -58.95 -29.83 0.00 0.00
NOPAT Less CapEx to Interest Expense
-2.37 -67.32 -19.00 -24.70 -41.53 -20.81 0.00 0.00
Payout Ratios
- - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% -0.61% 0.00% 0.00% 0.00% -1.95% 0.00% 0.00%

Quarterly Metrics And Ratios for Equillium

This table displays calculated financial ratios and metrics derived from Equillium's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
35,254,752.00 35,254,752.00 35,424,388.00 35,430,763.00 35,609,907.00 35,719,317.00 59,503,223.00 60,893,283.00 63,226,556.00 63,226,556.00 63,408,082.00
DEI Adjusted Shares Outstanding
35,254,752.00 35,254,752.00 35,424,388.00 35,430,763.00 35,609,907.00 35,719,317.00 59,503,223.00 60,893,283.00 63,226,556.00 63,226,556.00 63,408,082.00
DEI Earnings Per Adjusted Shares Outstanding
-0.08 0.01 0.00 -0.16 -0.24 -0.16 -0.07 -0.06 -0.08 -0.07 -0.07
Growth Metrics
- - - - - - - - - - -
Revenue Growth
20.39% 51.83% 37.10% -52.32% -100.00% -100.00% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
24.39% 97.15% 87.93% -91.83% -157.62% -5,247.71% -846.06% 28.95% 36.47% 11.20% -13.79%
EBIT Growth
25.99% 102.62% 91.02% -99.54% -178.19% -6,142.27% -1,221.01% 28.12% 36.33% 11.24% -13.62%
NOPAT Growth
32.06% 96.02% 81.26% -46.84% -217.81% -4,259.60% -573.79% 15.71% 36.75% 17.23% -10.34%
Net Income Growth
30.61% 114.00% 99.81% -147.40% -216.53% -1,326.28% -60,328.57% 34.85% 38.63% 18.23% -8.35%
EPS Growth
27.27% 110.00% 100.00% -166.67% -200.00% -1,700.00% 0.00% 143.75% 75.00% 75.00% 33.33%
Operating Cash Flow Growth
-10.07% 111.75% -301.10% 41.75% 7.17% -512.74% -10.11% 5.03% 47.35% -36.31% 54.63%
Free Cash Flow Firm Growth
-197.58% -189.59% -246.54% -28.37% 15.41% 17.35% 81.37% 74.50% 55.36% -1.28% -36.28%
Invested Capital Growth
55.53% 49.22% 87.84% 80.79% 64.94% 40.74% 19.22% 52.19% 53.24% 82.17% 70.52%
Revenue Q/Q Growth
16.05% 29.60% -12.21% -63.88% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-14.92% 96.81% -330.28% -1,116.84% -54.34% 33.82% 23.88% 8.61% -38.00% 7.51% 2.45%
EBIT Q/Q Growth
-11.61% 103.06% -448.45% -1,578.40% -55.60% 33.60% 23.82% 8.67% -37.81% 7.44% 2.48%
NOPAT Q/Q Growth
12.78% 94.88% -375.30% -592.05% -88.76% 29.79% 26.54% 13.42% -41.63% 8.11% 2.08%
Net Income Q/Q Growth
-16.74% 117.12% -101.50% -82,671.43% -49.36% 33.68% 26.29% 10.76% -40.69% 11.64% 2.34%
EPS Q/Q Growth
-33.33% 112.50% -100.00% 0.00% -50.00% 33.33% 62.50% 216.67% -185.71% 33.33% 0.00%
Operating Cash Flow Q/Q Growth
-55.37% 108.30% -1,148.90% 56.92% -147.62% 63.12% -179.82% 62.84% -37.28% 4.51% 6.87%
Free Cash Flow Firm Q/Q Growth
-13.18% 33.27% -87.88% 9.54% 25.42% 34.80% 57.65% -23.79% -30.59% -47.93% 43.01%
Invested Capital Q/Q Growth
38.82% 2.90% 75.15% -30.15% -11.67% -64.09% 66.13% 22.97% -9.23% 37.44% 43.99%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
-31.99% -0.79% -3.86% -129.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
-26.11% -0.72% -5.58% -106.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
-29.68% 0.70% -2.78% -129.17% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
-25.58% 3.38% -0.06% -131.92% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 106.64% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
86.16% 482.47% 2.07% 95.77% 98.04% 97.92% 94.74% 92.57% 94.50% 90.22% 90.34%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-48.17% -33.67% -19.52% -38.75% -88.32% -146.92% -90.24% -93.99% -54.39% -58.98% -43.92%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-19.50% 0.59% -2.85% -139.44% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
-16.80% 2.83% -0.06% -142.42% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-48.17% -33.67% -19.52% -38.75% -88.32% -146.92% -90.24% -93.99% -54.39% -58.98% -43.92%
Return on Equity Simple (ROE_SIMPLE)
-57.50% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-1.95 -0.10 -0.48 -3.29 -6.21 -4.36 -3.20 -2.77 -3.93 -3.61 -3.53
NOPAT Margin
-18.28% -0.72% -3.91% -74.89% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-1.80% 1.39% 1.30% -7.90% -10.45% -6.16% -3.48% -3.79% -3.65% -3.16% -2.43%
Return On Investment Capital (ROIC_SIMPLE)
-9.26% -0.45% -2.05% -17.26% -58.70% -86.23% -10.35% -9.70% -6.60% -6.44% -6.71%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
34.96% 22.70% 26.96% 40.44% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
91.15% 78.02% 78.63% 166.55% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
126.11% 100.72% 105.58% 206.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-3.17 0.10 -0.34 -5.67 -8.83 -5.86 -4.47 -4.08 -5.62 -5.20 -5.07
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-3.42 -0.11 -0.47 -5.71 -8.81 -5.83 -4.44 -4.06 -5.60 -5.18 -5.05
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
3.86 1.09 1.27 1.39 1.32 2.23 2.75 3.30 2.13 3.61 1.96
Price to Tangible Book Value (P/TBV)
3.86 1.09 1.27 1.39 1.32 2.23 2.75 3.30 2.13 3.61 1.96
Price to Revenue (P/Rev)
2.15 0.57 0.64 0.65 0.46 0.68 19.37 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
1.30 0.00 0.08 0.10 0.00 0.00 11.83 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.72 -1.65 -1.53 -1.52 -1.48 -1.63 -1.09 -1.11 -1.08 -1.12 -1.03
Leverage Ratio
2.29 2.06 1.90 1.83 1.90 2.01 1.27 1.21 1.14 1.16 1.08
Compound Leverage Factor
1.97 9.92 0.04 1.75 1.87 1.97 1.21 1.12 1.08 1.05 0.98
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-2.69 -3.81 -3.98 -6.42 -14.77 -22.36 6.45 8.36 17.01 41.25 14.77
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.91 2.08 3.04 3.93 2.70 1.65 10.85 10.58 18.62 23.40 19.49
Quick Ratio
1.68 1.94 2.79 3.55 2.42 1.59 10.70 10.32 18.33 23.07 18.92
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-16 -11 -20 -18 -13 -8.79 -3.72 -4.61 -6.02 -8.90 -5.07
Operating Cash Flow to CapEx
-46,315.79% 1,177.42% 0.00% -82,475.00% -204,225.00% 0.00% 0.00% -7,120.45% -143,366.67% -5,784.51% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.66 0.84 1.02 1.08 1.01 0.60 0.13 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
8.95 8.85 10.46 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
105.12 129.55 151.53 142.44 102.38 62.46 18.81 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
40.80 41.26 34.89 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
40.80 41.26 34.89 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-11 -11 -2.70 -3.51 -3.92 -6.44 -2.18 -1.68 -1.84 -1.15 -0.64
Invested Capital Turnover
-2.08 -2.64 -3.69 -3.77 -4.02 -1.91 -1.80 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
14 11 19 15 7.27 4.43 0.52 1.83 2.09 5.29 1.54
Enterprise Value (EV)
49 -8.86 3.60 3.93 -0.53 -0.24 52 64 65 145 50
Market Capitalization
81 24 29 27 14 11 85 94 126 202 103
Book Value per Share
$0.60 $0.64 $0.65 $0.54 $0.30 $0.14 $0.52 $0.47 $0.94 $0.89 $0.83
Tangible Book Value per Share
$0.60 $0.64 $0.65 $0.54 $0.30 $0.14 $0.52 $0.47 $0.94 $0.89 $0.83
Total Capital
21 22 23 19 11 5.06 31 29 59 56 53
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-32 -33 -26 -23 -15 -11 -33 -30 -61 -57 -53
Capital Expenditures (CapEx)
0.02 0.06 0.00 0.00 0.00 0.00 0.00 0.04 0.00 0.07 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-12 -12 -3.29 -3.95 -4.29 -6.78 -2.64 -2.17 -2.39 -1.67 -1.19
Debt-free Net Working Capital (DFNWC)
20 22 23 19 10 4.72 30 28 59 55 52
Net Working Capital (NWC)
20 22 23 19 10 4.72 30 28 59 55 52
Net Nonoperating Expense (NNE)
0.78 -0.57 -0.47 2.50 2.45 1.38 1.03 1.00 1.38 1.08 1.05
Net Nonoperating Obligations (NNO)
-32 -33 -26 -23 -15 -11 -33 -30 -61 -57 -53
Total Depreciation and Amortization (D&A)
-0.25 -0.21 -0.13 -0.03 0.02 0.03 0.03 0.02 0.02 0.03 0.02
Debt-free, Cash-free Net Working Capital to Revenue
-31.70% -27.17% -7.16% -9.62% -14.10% -40.94% -60.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
53.50% 50.95% 49.20% 45.31% 33.59% 28.50% 694.10% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
53.50% 50.95% 49.20% 45.31% 33.59% 28.50% 694.10% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.08) $0.01 $0.00 ($0.16) ($0.24) ($0.16) ($0.06) $0.07 ($0.06) ($0.04) ($0.04)
Adjusted Weighted Average Basic Shares Outstanding
35.25M 35.29M 35.42M 35.36M 35.59M 35.72M 65.32M 57.30M 96.28M 111.81M 111.92M
Adjusted Diluted Earnings per Share
($0.08) $0.01 $0.00 ($0.16) ($0.24) ($0.16) ($0.06) $0.07 ($0.06) ($0.04) ($0.04)
Adjusted Weighted Average Diluted Shares Outstanding
35.25M 36.59M 35.42M 35.36M 35.59M 35.72M 65.32M 57.30M 96.28M 111.81M 111.92M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
35.25M 35.42M 35.43M 35.61M 35.72M 59.50M 60.89M 63.23M 63.23M 63.41M 82.32M
Normalized Net Operating Profit after Tax (NOPAT)
-1.95 -0.07 -0.48 -3.29 -6.21 -4.36 -3.20 -2.77 -3.93 -3.61 -3.53
Normalized NOPAT Margin
-18.28% -0.51% -3.91% -74.89% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
-25.58% 3.38% -0.06% -123.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Equillium’s latest statements show a well-funded but still pre-revenue biotechnology company. As of June 30, 2026, Equillium had $57.2 million in cash and equivalents, compared with $11.1 million in Q2 2024. However, the company continues to report substantial operating losses and relies heavily on equity financing to fund research and development.

  • Cash reserves have improved substantially. Cash increased from $11.1 million in Q2 2024 to $57.2 million in Q2 2026, helped by common-stock issuances totaling approximately $64.0 million in Q3 2025 and Q1 2026.
  • Liquidity is strong relative to near-term obligations. Q2 2026 current assets totaled $58.0 million versus current liabilities of $2.5 million, producing a current ratio of roughly 23 times. Total liabilities were only $2.7 million, and the company reported no debt.
  • Quarterly operating losses have improved from early 2025 levels. The Q2 2026 net loss was $4.7 million, compared with $8.7 million in Q1 2025 and $5.7 million in Q2 2025. Operating expenses also declined to $5.2 million from $8.9 million in Q1 2025.
  • Operating cash burn has moderated. Cash used in operations was $4.1 million in Q2 2026, down from $8.2 million in Q1 2025 and $8.4 million in Q3 2025. At the latest quarterly burn rate, the existing cash balance could provide several years of funding, although clinical-development spending can fluctuate materially.
  • Interest income is providing a modest offset to operating expenses. Interest and investment income rose to $509,000 in Q2 2026 from $122,000 in Q2 2025, benefiting the company while its cash balance remains elevated.
  • The balance sheet is now concentrated in cash rather than investments. Equillium reported no short-term investments in Q2 2026, compared with $20.7 million to $22.2 million of short-term investments during the first three quarters of 2024. This simplifies liquidity analysis but may reduce investment income if cash yields decline.
  • Capital spending remains minimal. Purchases of property, plant and equipment were only $71,000 in Q2 2026, indicating that cash needs are driven primarily by research, development and corporate expenses rather than capital-intensive operations.
  • Equillium has not reported operating revenue in the recent periods provided. Revenue was zero in each quarter from Q1 2025 through Q2 2026, despite reported revenue of $10.7 million in Q1 2024, $13.9 million in Q2 2024, $12.2 million in Q3 2024 and $4.4 million in Q4 2024. The company currently has no recurring revenue stream to fund operations.
  • Net losses and accumulated deficits remain significant. Equillium lost $4.7 million in Q2 2026 and has retained earnings of negative $226.2 million. Research and development expense was $2.7 million in the latest quarter, while selling, general and administrative expense was $2.4 million.
  • Shareholder dilution is a major risk. Weighted-average basic shares outstanding increased from approximately 35.7 million in Q1 2025 to 111.8 million in Q2 2026. The recent equity raises strengthened the balance sheet, but future financing could further dilute existing shareholders.

Overall, Equillium’s financial position has improved because of substantial equity financing and a much larger cash balance. Nevertheless, the company remains dependent on capital markets while it reports no recent revenue, recurring operating losses and ongoing cash burn. Investors should focus on clinical progress, the timing of potential commercial revenue and whether future financing can be reduced without materially increasing dilution.

11/22/26 12:49 PM ETAI Generated. May Contain Errors.

Equillium Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Equillium's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Equillium's net income appears to be on an upward trend, with a most recent value of -$22.40 million in 2025, falling from -$13.25 million in 2018. The previous period was -$8.07 million in 2024. Check out Equillium's forecast to explore projected trends and price targets.

Equillium's total operating income in 2025 was -$23.63 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $23.63 million

Over the last 7 years, Equillium's total revenue changed from $0.00 in 2018 to $0.00 in 2025, a change of 0.0%.

In the past 12 quarters, Equillium's cash and equivalents has ranged from $11.06 million in Q2 2024 to $61.32 million in Q1 2026, and is currently $53.32 million as of their latest financial filing in Q3 2026.

Equillium had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2018.

Over the last 7 years, Equillium's book value per share changed from 3.74 in 2018 to 0.47 in 2025, a change of -87.4%.



Financial statements for NASDAQ:EQ last updated on 11/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners